


### Claims

1. (currently amended) The compound of claim 23, having the formula:



wherein

$R^1$  is a member selected from hydrogen, substituted or unsubstituted  $C_1$ - $C_4$  alkyl and substituted or unsubstituted  $C_{3-6}$  cycloalkyl;


$R^2$  is a member selected from substituted or unsubstituted phenyl, substituted or unsubstituted benzyl and substituted or unsubstituted  $C_3$ - $C_6$  cycloalkyl;

$R^3$  is a member selected from substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidyl, substituted or unsubstituted pyrazinyl, and phenyl substituted with a member selected from  $S(O)_nNR^{3a}R^{3b}$ ,  $NR^{3a}S(O)_nR^{3b}$ ,  $S(O)_nR^{3a}$ ,  $NR^{3a}R^{3b}$ ,  ~~$NR^{3a}C(O)R^{3b}$~~ ,  ~~$OC(O)R^{3b}$~~ ,  $OC(O)OR^{3b}$ ,  $C(O)R^{3b}$ , and  $C(O)NR^{3a}R^{3b}$  ~~and  $OR^{3a}$~~ ;

wherein  $R^{3a}$  and  $R^{3b}$  are members independently selected from H, substituted or unsubstituted  $C_1$ - $C_6$  alkyl and substituted or unsubstituted aryl; and

$n$  is a member selected from 0, 1 and 2.

2. (currently amended) The compound according to claim 1 wherein  $R^3$  has a formula which is a member selected from:




3. (previously presented) The compound according to claim 1, wherein  $R^1$  is a member selected from  $C_1$ - $C_3$  haloalkyl and methyl.

4. (previously presented) The compound according to claim 1, wherein  $R^2$  is cyclopentyl.

5-22. (canceled)

23. (currently amended) A compound having the formula:




wherein

$R^{10}$  is a member selected from hydrogen, hydroxy,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkyloxy,  $C_{3-6}$  cycloalkyl-oxy, halo and cyano;

$R^{11}$  is a member selected from substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidyl, substituted or unsubstituted  $C_{3-6}$  cycloalkyl, substituted or

unsubstituted phenyl, substituted or unsubstituted benzyl, and a group selected from (a) or (b):




wherein  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ , and  $R^{17}$  are members independently selected from hydrogen, halo, hydroxy, methyl, ethenyl, methoxy, ethoxy, nitro, trifluoromethyl, difluoromethyl, difluoromethoxy, trifluoroethoxy, trifluoromethoxy,  $OC_2H_5$ ,  $CH_2OH$ ,  $C(O)CH_3$ ,  $S(O)_nCH_3$ ,  $S(O)_nC_2H_5$  and cyano;

wherein n is 0, 1 or 2; ~~and~~

$R^{12}$  is a member selected from substituted ~~or unsubstituted~~ aryl, substituted or unsubstituted arylalkyl, and substituted or unsubstituted heteroaryl ~~and substituted or unsubstituted heteroarylalkyl~~.

wherein said substituted aryl is substituted with halo, methyl, ethenyl, amino, cyano, trifluoromethyl,  $CH_2OH$ ,  $S(O)_nR^{3a}R^{3b}$ ,  $NR^{3a}S(O)_nR^{3b}$ ,  $S(O)_nR^{3a}$ ,  $NR^{3a}R^{3b}$ ,  $OC(O)OR^{3b}$ ,  $C(O)R^{3b}$ ,  $C(O)NR^{3a}R^{3b}$ ,  $NH-C(=O)-NR^{3a}R^{3b}$ ,  $C(=NH)-NH_2$ ,  $NH-C(=S)-NHPh$ ,  $C(O)NH-OH$ , tetrazolyl,



$R^{3a}$  and  $R^{3b}$  are members independently selected from H, substituted or unsubstituted  $C_1-C_6$  alkyl and substituted or unsubstituted aryl.

24. (previously presented) The compound according to claim 23 in which at least one of  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ , and  $R^{17}$  is CN.


25. (previously presented) The compound according to claim 23 in which  $R^{13}$  is

halogen and R<sup>17</sup> is CN.


26. (currently amended) The compound according to claim 23 in which R<sup>12</sup> is selected from substituted phenyl, substituted or unsubstituted ~~phenyl~~, benzyl, pyridinyl, quinolinyl, pyridazinyl, pyrazinyl, and pyrimidinyl.

27. (currently amended) The compound according to claim 26 in which said substitutions on said benzyl, pyridinyl, quinolinyl, pyridazinyl, pyrazinyl or pyrimidinyl include up to 2 members independently selected from halo, methyl, ethenyl, amino, nitro, cyano, trifluoromethyl, ethoxy-carbonyl, C(O)OH, C(O)OCH<sub>3</sub>, S(O)<sub>2</sub>NH<sub>2</sub>, C(O)NH<sub>2</sub>, C(O)NHC<sub>2</sub>H<sub>5</sub>, NHS(O)<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>OH, S(O)<sub>2</sub>CH<sub>3</sub>, SCH<sub>3</sub>, and SC<sub>2</sub>H<sub>5</sub>.

28. (currently amended) The compound according to claim [[27]] 23, wherein said R<sup>12</sup> is substituted phenyl, and said substituted phenyl is a member selected from




29. (previously presented) The compound according to claim 28 wherein said compound is a member selected from:




30. (currently amended) The compound according to claim [[23]] 42 in which R<sup>10</sup> is halogen;

R<sup>11</sup> is a member selected from substituted pyridinyl, substituted pyrimidyl, and a group selected from (a) or (b):






wherein R<sup>21</sup> is halogen and R<sup>22</sup> is a member selected from H, CH<sub>3</sub>,



32. (currently amended) The compound of claim [[23]] 42, having the formula:



wherein

R<sup>12</sup> is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; and

R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, and R<sup>17</sup> are members independently selected from H, halogen, and CN.


33. (previously presented) The compound according to claim 32 in which at least one of  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ , and  $R^{17}$  is CN.

34. (previously presented) The compound according to claim 32 in which  $R^{13}$  is halogen and  $R^{17}$  is CN.

35. (previously presented) The compound according to claim 32 in which  $R^{12}$  is substituted or unsubstituted phenyl.

36. (previously presented) The compound according to claim 35 in which said substituted phenyl is substituted with a member selected from  $S(O)_2NH_2$  and  $C(O)NH_2$ .

37. (previously presented) The compound according to claim 36 wherein said substituted phenyl is a member selected from:




38. (previously presented) A pharmaceutical composition comprising the compound of claim 23.

39. (withdrawn) A method of treating HIV infection in a human subject comprising administering to said subject the compound of claim 23 in an amount sufficient to treat said HIV infection.

40. (withdrawn) A method of inhibiting HIV replication in a cell, comprising contacting said cell with the compound of claim 23 in an amount sufficient to inhibit said HIV replication.

41. (withdrawn) A method of inhibiting reverse transcriptase in a cell, comprising contacting said cell with the compound of claim 23 in an amount sufficient to inhibit said reverse transcriptase.


42. (new) A compound having the formula:



wherein:

$R^{10}$  is halogen;

$R^{11}$  is a member selected from substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrimidyl, substituted or unsubstituted  $C_{3-6}$  cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, and a group selected from (a) or (b):



wherein  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ , and  $R^{17}$  are members independently selected from hydrogen, halo, hydroxy, methyl, ethenyl, methoxy, ethoxy, nitro, trifluoromethyl, difluoromethyl, difluoromethoxy, trifluoroethoxy, trifluoromethoxy,  $OC_2H_5$ ,  $CH_2OH$ ,  $C(O)CH_3$ ,  $S(O)_nCH_3$ ,  $S(O)_nC_2H_5$  and cyano;

$n$  is 0, 1 or 2; and

$R^{12}$  is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl.

43. (new) A pharmaceutical composition comprising the compound of claim 42.

44. (new) A method of treating HIV infection in a human subject comprising administering to said subject the compound of claim 42 in an amount sufficient to treat said HIV infection.



45. (new) A method of inhibiting HIV replication in a cell, comprising contacting said cell with the compound of claim 42 in an amount sufficient to inhibit said HIV replication.

46. (new) A method of inhibiting reverse transcriptase in a cell, comprising contacting said cell with the compound of claim 42 in an amount sufficient to inhibit said reverse transcriptase.